Economic impact of extended treatment with peginterferon α-2a and ribavirin for slow hepatitis C virologic responders

Journal of Viral Hepatitis

Volumn 15, Issue 4, 2008, Pages 293-299

  Nakamura, J ^a,b   Toyabe, S I ^b   Aoyagi, Y ^b   Akazawa, K ^b  

^a Niigata University Graduate School of Medical and Dental Sciences ^*  (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Combination therapy; Economic impact; Extended treatment; Peginterferon; Ribavirin; Slow virologic responders

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; GENOTYPE; HEPATITIS C; HUMAN; LIFE EXPECTANCY; MALE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STANDARD; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MODELS, STATISTICAL; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 40349093317     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00943.x     Document Type: Article

References (37)

1. World Health Organization (WHO). Available at: http://www.who.int/ vaccine_research/disease/viral_cancers/en/index2/htm : accessed January 13, 2007.
2. Bosch FX, Ribes J, Borras J. Epidemiology of liver cancer. Semin Liver Dis 1999 19 : 271 285.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 965.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 13 : 975 982.
5. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003 98 : 2354 2362.
6. Sullivan SD, Craxi A, Alberti A et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004 22 : 257 265.
7. Berg T, Wagner MV, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 130 : 1086 1097.
8. Beck JR, Pauker SG. The medical process in medical prognosis. Med Decis Making 1983 3 : 419 458.
9. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993 13 : 322 338.
10. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993 88 : 240 243.
11. Yano M, Kumada H, Kage M et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996 23 : 1334 1340.
12. Shibata M, Morizane T, Uchida T et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998 351 : 1773 1777.
13. Kaneko S, Unoura M, Takeuchi M et al. The role of hepatitis C virus in hepatocellular carcinoma in Japan. Intervirology 1994 37 : 108 113.
14. Serfaty L, Aumaitre H, Chazouilleres O et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998 27 : 1435 1440.
15. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004 53 : 744 749.
16. Kato Y, Nakata K, Omagari K et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 1994 74 : 2234 2238.
17. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995 346 : 1051 1055.
18. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993 18 : 47 53.
19. Tanaka K, Sakai H, Hashizume M, Hirohata T. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn J Cancer Res 1998 89 : 1241 1250.
20. Miyakawa H, Izumi N, Marumo F, Sato C. Roles of alcohol, hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Alcohol Clin Exp Res 1996 20 : 91A 94A.
21. Planas R, Ballesé B, Álvarez MA et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004 40 : 823 830.
22. Bennett WG, Inoue Y, Beck R, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997 127 : 855 865.
23. Trevisani F, Magini G, Santi V et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during survival. Am J Gastroenterol 2007 101 : 1 10.
24. Ikai I, Takayasu K, Omata M et al. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol 2006 41 : 884 892.
25. Forman LM, Lewis JD, Berlin JA, Feldman JI, Lucey MR. The association between hepatitis C and survival after orthotopic liver transplantation. Gastroenterology 2002 122 : 889 896.
26. Available at: http://www.mhlw.go.jp/toukei/saikin/hw/life/life05/hyo-m. html ; accessed at 5 March 2007. Abridged Life Table for Japan, 2004. Tokyo : Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour, and Welfare, 2005.
27. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for naïve patients with chronic hepatitis C. J Hepatol 2000 33 : 651 658.
28. OECD. Main Economic Indicators. Paris, France : OECD, 2006.
29. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006 43 : 1303 1310.
30. Siebert U, Sroczynski G, Rossol S et al. Cost effectiveness of peginterferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003 52 : 425 432.
31. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996 276 : 1253 1258.
32. National Institutes of Health. Consensus Development Conference Statement: Management of Hepatitis C, June 2002. Available at: http://www.consensus.nih.gov : accessed at 2 March 2007.
33. Strader DB, Wright T, Thomas DL, Seeff LB, The American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 1171.
34. Hadziyannis SJ, Sette H, Jr. Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004 140 : 346 357.
35. Pearlman B, Ehleben C, Saifee S. Improved virologic response rates with treatment extension to 72 weeks of peginterferon alfa-2b plus weight-based ribavirin in a difficult-to-treat population of genotype 1-infected slow responders. 57th AASLD, Boston, MA, October 27-31, 2006 (Abstract 343).
36. Davis GL, Wong JB, McHutchson JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 652.
37. Sánchez-Tapias JM, Diago M, Escartín P et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 131 : 451 460.